Conformis (Nasdaq:CFMS) +  shares ticked up today on first-quarter results that came in ahead of the consensus forecast.

Shares of CFMS rose more than 1% at $1.36 per share by afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell slightly.

The Billerica, Massachusetts-based orthopedic device maker posted losses of $9.57 million. That amounts to $1.32 per share on sales of $12.84 million for the three months ended March 31, 2023. Its losses per share came in 7¢ ahead of Wall Street predictions. Sales topped analysts’ expectations of $12.57 million in revenue, too.

Conformis recorded nearly halved its losses from the same time last year on a sales decline of 17.45%.

The company attributed its product revenue slide to declines in U.S. knee orders, according to a news release. This comes on the heels of a change in Conformis’ business model, as well as manufacturing and supply chain challenges.

Conformis declined to provide full-year guidance for 2023. The company expects revenues to range between $11 million and $13 million in the second quarter of the year.